Myeloproliferative Neoplasm
Conditions
Brief summary
The PERIBLOOD-MPN study aims to develop and validate a minimally invasive peripheral blood test using single-cell RNA sequencing to accurately diagnose and classify myeloproliferative neoplasms, potentially reducing the need for invasive bone marrow biopsies.
Detailed description
PERIBLOOD-MPN is an observational, multi-center study that aims to collect data to develop a novel, minimally invasive diagnostic tool for myeloproliferative neoplasms (MPN) based on peripheral blood (PB) profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing (scRNA-seq). Current diagnostic practice relies on bone marrow (BM) biopsy, a procedure that is invasive, technically demanding, and may be inconclusive in early or prefibrotic disease stages. Prior work in the field has established a reference atlas of healthy cHSPC subtypes and a computational pipeline capable of identifying disease-specific transcriptional changes by quantifying deviations from this reference. This study will assess whether PB-based genomic profiling can accurately distinguish MPN from non-clonal cytoses, including secondary erythrocytosis or thrombocytosis. Patients referred for a bone marrow biopsy due to suspected myeloproliferative neoplasm (MPN) will undergo PB collection for genomic profiling. The primary objective is to develop a PB-based test by comparing the new test's diagnoses to conventional BM-based diagnostics. The secondary objectives include evaluating its potential for MPN subtype classification and risk stratification, as well as assessing its ability to reduce the need for BM biopsies.
Interventions
DIAGNOSTIC_TESTPERIBLOOD-MPN
Observational intervation of cHSPCs
Sponsors
Weizmann Institute of Science
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. Age ≥ 18 years 2. Confirmed MPN diagnosis, based on the WHO criteria (Barbui 2018), which includes: Polycythemia Vera (PV) Criteria: * Elevated hemoglobin (\>16.5 g/dL for men, \>16.0 g/dL for women), hematocrit (\>49% for men, \>48% for women), or increased red cell mass * Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis) * Presence of JAK2 mutation (V617F or exon 12) Essential Thrombocythemia (ET) Criteria: * Platelet count ≥450 ×10⁹/L * Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage * Not meeting WHO criteria (Alaggio et al., 2022) for other myeloid neoplasms (such as CML, PV, PMF, MDS). * Presence of JAK2, CALR, or MPL mutation Primary Myelofibrosis (PMF) Criteria * Megakaryocytic proliferation and atypia, with or without reticulin fibrosis, and increased marrow cellularity (for prefibrotic/early PMF) or significant reticulin/collagen fibrosis (for overt PMF) * Not meeting criteria for other myeloid neoplasms * Presence of JAK2, CALR, or MPL mutation, or in their absence, another clonal marker 3. Patients who are referred for a bone marrow biopsy due to a suspected diagnosis of MPN
Exclusion criteria
1. Patients diagnosed with MPN receiving therapy 2. Patients who have undergone a bone marrow transplant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To development PERIBLOOD-MPN Diagnostic Test | Three months following the PB sample | Development of PERIBLOOD-MPN Diagnostic Test Using PB-Derived CD34+ cHSPCs for Diagnosis of MPN |
Contacts
CONTACTLiran Shlush, Prof.
CONTACTGil Gonen Yaacovi, PhD
Outcome results
None listed